Navigation Links
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Date:2/28/2008

and in the ROW at year end.

During the fourth quarter of 2007, the Company received six generic product approvals in the U.S. from the FDA, including tentative approvals, and 39 approvals, representing 28 molecules, from regulatory bodies in Europe and in the ROW.

Proprietary Products

The Company currently has an extensive proprietary clinical development program that includes four products in Phase III studies and three New Drug Applications pending at the FDA.

Selling, General and Administrative

The Company's SG&A expenses for the quarter and year ended December 31, 2007 totaled $207 million and $764 million, respectively. SG&A for 2007 included a charge of $15.3 million for litigation related to the Ovcon(R) oral contraceptive product.

Interest Expense/Income and Other Income

During 2007, the Company recorded $159 million of interest expense, almost all of which is related to interest on the debt incurred in connection with the PLIVA acquisition. In addition, during 2007, the Company recorded interest income of $33 million and other income of $21 million.

Stock-Based Compensation

During 2007, the Company recorded stock-based compensation expenses of $27.8 million, or $0.17 per share. For the fourth quarter of 2007, the Company recorded stock-based compensation expenses of $4.4 million, or $0.03 per share. The impact of stock-based compensation for the year and quarter ended December 31, 2007 is allocated among cost of sales, SG&A and R&D.

Tax Rate

The Company's tax rate for the quarter and year ended December 31, 2007 was 28.1% and 31.1%, respectively. The tax rate for the year includes a one- time $9.6 million benefit from a reduction in deferred income taxes as a result of Germany's enactment of a lower corporate income tax rate.

Balance Sheet

The Company's cash, cash equivalents and marketable securities totaled approximately $551 million. At December 31, 2007, the Comp
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 The U.S. Department of Labor ... University Edwardsville as part of the Trade Adjustment Assistance ... is co-administered by the Department of Labor and Department ... Labor Thomas E. Perez and Secretary of Education Arne ... training grants to nearly 270 colleges across the country. ...
(Date:9/30/2014)... September 30, 2014 Applying a well-known optical ... at Harvard University has demonstrated the ability to ... work that holds promise for making future, flexible ... the sides of next-gen rocket ships and spacecraft ... passes through oil in water, it becomes iridescent, ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... trends and segments with highest potential revenues Do ... Visiongain,s updated report gives you revenue predictions for ... ahead. For those therapies you find financial data, ... new analysis you get sales forecasts to 2024 ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Proove ... medicine, is excited to announce a new genetic test ... The Proove Pain Perception Test will provide physicians ... and why pain tolerance levels are stratified between individuals. ... identify whether a person has a genetic predisposition that ...
Breaking Biology Technology:U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Taking thin films to the extreme 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... Principle Reached to Terminate Marketing Agreement with Triax ... on Most Favorable Terms, NAPA, Calif., May 15 ... company engaged in the development,of technologies that target the ... quarter ended March 31, 2008 and an agreement in,principle ...
... May 15 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) ... & Renshaw 5th Annual Global Healthcare Conference on,May 19, ... and at the 2008 UBS,Global Generic and Specialty Pharmaceuticals ... time (5:00 a.m. EDT). The presentations will,be web cast ...
... Mass., May 15 Hologic, Inc. (Nasdaq:,HOLX) today ... be,presenting at the Citigroup Investment Research Global Healthcare,Conference ... the Hilton Hotel in New York,NY., Interested ... audio webcast of,Hologic,s investor presentation on Thursday, May ...
Cached Biology Technology:Senetek PLC Reports First Quarter 2008 Financial Results 2Senetek PLC Reports First Quarter 2008 Financial Results 3Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 2Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences 3
(Date:9/30/2014)... suite of perilous threats in today,s ocean. From ... change, fragile coral ecosystems are disappearing at unprecedented ... species of corals surrounding the island of Moorea ... their tropical environment: coral guard-crabs. New research from ... Station scientist Seabird McKeon and the museum,s predoctoral ...
(Date:9/30/2014)... 2014 Winners of The Economist,s prestigious Innovation ... to take place at the JW Marriott Hong Kong on Friday, ... will share their experiences and the lessons those hold for others. ... innovation over the past decade, will be presented at a ceremony ... summit. It will be the first time the ceremony has come ...
(Date:9/29/2014)... new study confirms that the exposure to tar tended ... of regular cigarettes. Similarly, exposure to nicotine tended ... popular type of cigarette in several countries around the ... certain toxic chemicals in the smoke of these cigarettes ... lower levels of chemicals in the smoke are not ...
Breaking Biology News(10 mins):Smithsonian scientists discover coral's best defender against an army of sea stars 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Slim cigarette smokers not exposed to more harmful chemicals 2
... activity resource, a personal assistant - computers are ubiquitous. ... lot to be desired: they rapidly become obsolete, typically ... components that are difficult to recycle. Moreover, they consume ... release of CO2 into the atmosphere. Employees at ...
... a vital element not only for plants but also ... have been faced with a growing shortage of this ... been steadily increasing. It is therefore high time to ... task, because phosphorus cannot be replaced by any other ...
... a biological marker that may help to identify ... rapid-acting antidepressant. The brain signal, detectable by noninvasive ... mechanism, which are vital for drug development, say ... is among the latest of several such markers, ...
Cached Biology News:Eco-computer with a natural wood look 2Using wastewater as fertilizer 2Using wastewater as fertilizer 3Brain signal IDs responders to fast-acting antidepressant 2Brain signal IDs responders to fast-acting antidepressant 3Brain signal IDs responders to fast-acting antidepressant 4Brain signal IDs responders to fast-acting antidepressant 5Brain signal IDs responders to fast-acting antidepressant 6
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
Biology Products: